Navigation Links
Misonix Announces New Distribution Agreement for Belgium and Luxembourg
Date:4/1/2009

FARMINGDALE, N.Y., April 1 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with Sophysa Benelux, based in Braine l'Alleud, Belgium, for the distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator and the BoneScalpel(TM) Ultrasonic Bone Cutter.

The agreement provides Sophysa with the rights to sell in Belgium and Luxembourg, and includes minimum purchase requirements.

Sophysa is acknowledged as a market leader and has built a reputation as a distributor of state-of-the-art medical devices and capital equipment, with special emphasis in neuro and spine surgery.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone shaving technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the potential hazards associated with rotary sharps.

"Misonix welcomes Sophysa Benelux to our growing sales and distribution organization. We know Sophysa as a first tier distributor of advanced medical equipment in the Benelux countries," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Sophysa has established themselves as a quality distribution partner for successfully introducing high tech medical devices to their markets. We are particularly pleased that they will be distributing two of our product platforms through their well established channels."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward-looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Misonix Contact:                 Investor Relations Contact:
    Richard Zaremba                  Kevin McGrath / Cameron Associates, Inc.
    631-694-9555                     212-245-4577
    invest@misonix.com               Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces New Sales Agency Agreement for Eastern Europe
2. Misonix Announces New Distribution Agreement for Israel
3. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
4. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
5. Misonix Announces New HIFU Distribution Agreement for Italy
6. Misonix Announces Extension and Expansion of Distribution Agreement With Mentor Corporation
7. Misonix Reports First Quarter Fiscal Year 2009 Financial Results
8. Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern
9. Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study
10. Misonix To Present at The Rodman & Renshaw 10th Annual Healthcare Conference
11. Waters Corporation Announces the Purchase of UPLC/MS Systems by the National Cancer Institute for Advanced Metabolomics Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... In its just released 2018 ... and Harry Nelson. This is the third consecutive year that Hardiman and Mills have ... were both recognized for expertise in Health Care Law while Mills was recognized in ...
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article on NextShark ... surgery, largely influenced by the growing popularity of “pretty boys” in both K-Pop and ... standards of male appearance are changing not only in the Asian nation, where plastic ...
(Date:8/17/2017)... ... 17, 2017 , ... Inc. Magazine Unveils 36th Annual List of America’s Fastest-Growing ... Growth of 3,004.8% , NEW YORK, August 16, 2017 – Inc. magazine today ranked ... of the nation's fastest-growing private companies. The list represents a unique look at the ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Centrifugation is more ... in the laboratory that we can no longer do without. And just like a ... of your device. , In this webinar, attendees will learn about the most important ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Summer days ... Island’s original family-owned supermarket, has put together suggestions for enjoying the season of sunshine. ... or activity, everyone in the family can join in on the fun. , ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... Aug. 1, 2017   CerSci Therapeutics , a ... Texas , has received notice from the National ... of Health (NIH) that it has been awarded a ... over $650,000 in 2017 with an additional $1,000,000 to ... New Drug application of their lead non-opioid drug candidate ...
(Date:7/28/2017)... --EnvoyHealth, a Diplomat company, has partnered with Compliance Meds ... a technology designed to improve patient medication adherence. ... solutions and services that help track and improve patients, ... LITE offers medication monitoring and control for patients and ... Records date and time of bottle ...
(Date:7/26/2017)... BEACH, Fla. , July 26, 2017 ... of enrollment of our clinical trial evaluating Altemia TM ... Cell Anemia (SCA) and Sickle Cell Disease (SCD). The ... to evaluate the efficacy and safety of Altemia TM ... trial is conducted under US IND 125274. ...
Breaking Medicine Technology: